Atara Biotherapeutics, Inc. (ATRA) insider trading.
In Q3 2026, insiders at Atara Biotherapeutics, Inc. reported 4 non-derivative transactions on 4 Forms 3, 4 and 5: 1 open-market purchase worth $1000K and 1 sale worth $41K.
- Transactions
- 4
- Purchases (P)
- 1
- Sales (S)
- 1
- Net shares, P minus S
- 99,104
- Insiders
- 3
- Last filed
- 2026-09-04
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Redmile Group, LLC / Green Jeremy | Director | 2 | 0 | 0 |
| Cherry Brian N | Director | 1 | 1 | 0 |
| Nguyen AnhCo | Director, Officer · President and CEO | 1 | 0 | 1 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-04 | Cherry Brian N | P (A) | 104,166 | $9.6 | 166,486 | Form 4 |
| 2026-08-17 | Nguyen AnhCo | S (D) | 5,062 | $8.08 | 132,775 | Form 4 |
| 2026-07-22 | Redmile Group, LLC / Green Jeremy | F (D) | 60 | — | 636,852 | Form 4 |
| 2026-07-22 | Redmile Group, LLC / Green Jeremy | M (A) | 195,211 | — | 636,912 | Form 4 |
Transaction codes in this quarter
Get ATRA insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1604464&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · ATRA company page · Atara Biotherapeutics, Inc. on SEC.gov
Questions
Are insiders buying or selling Atara Biotherapeutics, Inc. (ATRA)?
In Q3 2026, insiders at Atara Biotherapeutics, Inc. reported 4 non-derivative transactions on 4 Forms 3, 4 and 5: 1 open-market purchase worth $1000K and 1 sale worth $41K. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Atara Biotherapeutics, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/atra.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.